- Confirmed disability progression as a marker of permanent disability in multiple sclerosis2022 | First Faculty of Medicine
- A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients2016 | First Faculty of Medicine
- Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression2021 | First Faculty of Medicine
- Commentary : Sustained reduction in disability progression in patients with primary progressive multiple sclerosis - follow-up study ORATORIO2020 | Faculty of Medicine in Pilsen
- Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE2018 | First Faculty of Medicine
- MRI correlates of disability progression in patients with CIS over 48 months2014 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS2017 | First Faculty of Medicine
- A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS2019 | First Faculty of Medicine
- Impact of sustained disability progression and relapses on visual outcomes in the AFFIRM trialPublication without faculty affiliation
- Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years2013 | First Faculty of Medicine
- Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study2019 | First Faculty of Medicine
- Monitoring of Lymphocyte Populations During Treatment with Interferon--1b to Predict Multiple Sclerosis Disability Progression2019 | Faculty of Medicine in Hradec Králové
- Patients' Stratification and Correlation of Brain Magnetic Resonance Imaging Parameters with Disability Progression in Multiple Sclerosis2009 | First Faculty of Medicine
- Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis A 5-year longitudinal study2009 | First Faculty of Medicine
- No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a2018 | First Faculty of Medicine
- Is magnetic resonance imaging a reliable tool for prediction of disability progression in patients with early relapsing-remitting multiple sclerosis? A 5-year longitudinal studyPublication without faculty affiliation
- Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes2015 | Third Faculty of Medicine
- Assessment of T2 lesion-based disease activity volume outcomes in predicting disease progression in multiple sclerosis over 10 years2022 | First Faculty of Medicine
- Measurement of Corpus Callosum and Comparison of MRI Techniques for Monitoring of Multiple Sclerosis2012 | First Faculty of Medicine
- Real-Life Outcome in Multiple Sclerosis in the Czech Republic2019 | First Faculty of Medicine
- Microsatellite Polymorphism in Haem Oxygenase 1 Gene Promoter in Multiple Sclerosis2012 | First Faculty of Medicine
- Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies2017 | First Faculty of Medicine
- Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome2015 | First Faculty of Medicine
- Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients2017 | First Faculty of Medicine
- Research Report University Hospital clinical trial 101MS326Publication without faculty affiliation
- Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years : A Longitudinal Study2013 | First Faculty of Medicine
- Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study2018 | First Faculty of Medicine
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis2010 | Second Faculty of Medicine
- Long-term therapy of multiple sclerosis with fingolimod - results of 4.5-year extension study to TRANSFORMS2016 | Publication without faculty affiliation
- Long--term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data2023 | Faculty of Medicine in Hradec Králové